NCT02094378View on ClinicalTrials.gov

A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

Esketamine

84 mg esketamine administered intranasally

DRUG

Placebo

Placebo administered intranasally

Trial Locations (1)

Unknown

Leiden

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02094378 - A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects | Biotech Hunter | Biotech Hunter